

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
10/782,271	02/18/2004	Borzu Sohrab	LSI0086/US/3	4224	
33072 KAGAN BIND	7590 02/21/200 ER. PLLC	EXAMINER			
SUITE 200, MA	APLE ISLAND BUILI	BERHANU, ETSUB D			
221 MAIN STR STILLWATER,			ART UNIT	PAPER NUMBER	
<u> </u>			3768		
SHORTENED STATUTORY	Y PERIOD OF RESPONSE	MAIL DATE	DELIVERY MODE		
3 MON	NTHS	· 02/21/2007	PAPER		

Please find below and/or attached an Office communication concerning this application or proceeding.

If NO period for reply is specified above, the maximum statutory period will apply and will expire 6 MONTHS from the mailing date of this communication.

			Application No.	Applicant(s)			
Office Action Summary		10/782,271	SOHRAB, BORZU				
		Ī	Examiner	Art Unit			
			Etsub D. Berhanu	3768			
Period fo	The MAILING DATE of this commun or Reply	nication appe	ears on the cover sheet with the	correspondence address			
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication. - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication. - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).							
Status							
1)⊠	Responsive to communication(s) file	ed on <u>24 Nc</u>	ovember 200 <u>6</u> .	· ·			
			action is non-final.				
3)	Since this application is in condition for allowance except for formal matters, prosecution as to the merits is						
	closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11, 453 O.G. 213.						
Dispositi	on of Claims						
4)🖂	4)⊠ Claim(s) <u>10-16 and 18-20</u> is/are pending in the application.						
4	4a) Of the above claim(s) is/a	are withdraw	n from consideration.				
5)	Claim(s) is/are allowed.			•			
	Claim(s) <u>10-16 and 18-20</u> is/are reje	ected.					
·	Claim(s) is/are objected to.						
8)	Claim(s) are subject to restrict	ction and/or	election requirement.				
Applicati	on Papers						
9)☐ The specification is objected to by the Examiner.							
10) ☐ The drawing(s) filed on is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.							
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).							
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).							
11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.							
Priority u	inder 35 U.S.C. § 119	•					
 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of: 1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No. 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. 							
Attachment(s)							
1) Notice of References Cited (PTO-892) 4) Interview Summary (PTO-413) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) Paper No(s)/Mail Date.							
3) Information Disclosure Statement(s) (PTO/SB/08) Paper No(s)/Mail Date 11/06/06.			5) Notice of Informal 6) Other:				

DETAILED ACTION

1. The text of those sections of Title 35, U.S. Code not included in this action can be found in a prior Office action.

Claim Rejections - 35 USC § 102

2. Claims 10-16, 18 and 19 are rejected under 35 U.S.C. 102(b) as being anticipated by Say et al.'752 (previously cited).

See rejection in prior Office Action.

Claim Rejections - 35 USC § 103

3. Claims 10 and 20 are rejected under 35 U.S.C. 103(a) as being unpatentable over Aceti et al. '675 (previously cited) further in view of Say et al. '752.

See rejection in prior Office Action.

Response to Arguments

4. Applicant's arguments filed 24 November 2006 have been fully considered but they are not persuasive. Applicant argues on page 1 of the Remarks that "Say et al.'752 does not disclose, teach or otherwise suggest modifying a measurement schedule subsequent to administering insulin as claimed." Examiner notes that automatically measuring the glucose concentration includes obtaining signals from the sensor circuit, processing the data, and transferring the data to the display device. Therefore, the rate at which the data is processed and transmitted/displayed is part of a measurement schedule. Say et al.'752 teaches modifying a scheduling mode as a result of sensing hypoglycemia or hyperglycemia in a patient and administering insulin to a patient based on the detected hypoglycemic or hyperglycemic event

(col. 43, lines 13-20). Because the method of Say et al.'752 is performed continuously, the steps disclosed by Say et al.'752 are constantly repeated, indicating that after insulin has been administered to a patient, the steps of monitoring the glucose levels, detecting hypoglycemic or hyperglycemic events, and modifying the scheduling mode are all performed once again. Therefore, the step of modifying the scheduling mode is performed after an administration of insulin to a patient. Examiner further notes that Say et al.'752 also teaches modifying drug administration protocols subsequent to administering insulin to a patient (col. 55, lines 32-50), wherein determining drug administration protocols (low and high glucose level thresholds and proper drug distribution amounts/intervals) include monitoring a patient's blood glucose levels and determining hypoglycemic and hyperglycemic events in the patient. For the reasons discussed above, the rejection of claims 10-16 and 18-20 are upheld.

Conclusion

5. THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Etsub D. Berhanu whose telephone number is 571.272.6563. The examiner can normally be reached on Monday - Friday (Every other Friday off).

Art Unit: 3768

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Eleni Mantis-Mercader can be reached on (571)272-4740. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

EDB